Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind lot-consistency study of HB-AS02V hepatitis B vaccine in healthy adults
2005-004057-98Phase 3Completed
- Sponsor
- Henogen
- Start
- Nov 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adjuvanted hepatitis B vaccine HB-AS02V in hepatitis B (HBV) (3 arms), sponsored by Henogen. Primary endpoint: Anti-HBs seroprotection rate at Month 2. Started Nov 2007; status: completed.
02
Drugs
adjuvanted hepatitis B vaccine HB-AS02V
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2005-004057-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004057-98.